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Abstract 
 While diseases such as cancer and diabetes, or surgery and traumatic injury can cause 
hypoxia through a decrease in blood circulation to bodily regions or decrease cardiac output they 
can also associate with hypoxia-induced pain. Clinically, opioids, such as morphine, are used to 
modulate pain. The mu-opioid receptors (MORs) are one of three main types of opioid receptors 
and are key mediators in morphine-induced analgesia. Therefore, in this study, the effect of 
hypoxia on MOR gene expression was examined using human neuronal cells treated with DFO to 
create a hypoxic-mimic condition.  We found that MOR expression was shown to decrease over 
increased exposure times to DFO. Recently, our laboratory reported that receptor associated C 
kinase (RACK-1), interacting with the transcription regulator Poly C Binding Protein (PCBP-1), 
can negatively regulate MOR gene expression using a yeast two-hybrid screening system. RT-
PCR analysis revealed an increased in RACK-1 expression while a decrease in MOR expression 
under DFO treatment was observed. These results supported our recent finding that RACK-1 
participates in the regulation of MOR expression. Neuronal cells surviving the DFO insult also 
displayed activation of the JAK/STAT pathway through Western blot analysis. Due to activation, 
the suppressors of cytokine signaling (SOCS) proteins, negative regulators of the JAK/STAT 
pathway, were investigated and detected via RT-PCR. These results suggest that there is an up-
regulation of the SOCS proteins under hypoxia, and it may play a role in a form of neuroprotection 
by aiding in the decrease of inflammation associated with the JAK/STAT pathway.  
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Introduction 
 Disease is a term defined as a condition that affects a living organism, which impairs 
normal function, and is typically evident by distinguishing signs or symptoms. Diseases like 
diabetes affect 23.6 million people in the United States, according to the National Institute of 
Health. Patients with conditions such as physical trauma, cardiac arrest, pneumonia, stroke, 
diabetes, or cancer are considered to be enduring a disease, which can be identified by signs or 
symptoms that affect the associated bodily region. These diseases, and many others, share a 
common symptom: hypoxia. While diseases such as diabetes cause hypoxia through a decrease in 
blood circulation to the bodily regions, operation and post-operative events can also result in 
hypoxia by decreasing cardiac output due to the use of anesthesia. Since hypoxia is a symptom, as 
well as an outcome, within disease, it has become an important event to be investigated. 
 Hypoxia is a shortage in the supply of oxygen available for cellular consumption. The stress 
presented upon cells under hypoxia causes a reduction in the amount of ATP within the cell. For 
example, neurons under hypoxia are unable to maintain membrane potential and result in 
depolarization, calcium influx, and eventually cell death (Won et al, 2002). Hypoxia is a condition 
that is noxious to normal cells and cancer cells, however cancer cells have the ability to adapt to 
the low oxygen environment through the development of changes that allow them to survive as 
well as proliferate (Harris, 2002).  
 To survive a hypoxic assault, neurons enlist mechanisms that perpetuate survival and 
adaptation. One of the mechanisms that cells utilize in response to hypoxia involves a transcription 
factor known as hypoxia-inducible factor-1 (HIF-1) (Michiels, 2004; Vangeison et al, 2008). HIF-
1 can up-regulate or down-regulate the expression of assorted genes against the hypoxic insult 
(Vangeison et al, 2008; Gao et al, 2013). This transcription factor is composed of two subunits, 
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HIF-1𝛼 and HIF-1𝛽. Under normoxia, HIF-1𝛼 interacts with the Von Hippel-Lindau (VHL) tumor 
suppressor protein, a component of the E3 ubiquitin ligase complex (Warnecke et al, 2003). The 
oxygen sensation mechanism utilized for HIF-1𝛼/VHL complex recognition is comprised of the 
oxygen dependent enzymatic hydroxylation of two conserved proline residues (Warnecke et al, 
2003). The enzymes for these reactions are known as prolyl hydroxlases (PHDs) and are essential 
for the proteaosomal degradation of HIF-1𝛼. This interaction causes ubiquitination of HIF-1𝛼 and 
leads to its labeling for proteaosomal degradation. Under hypoxia, HIF-1𝛼 accumulates and 
translocates into the nucleus where it forms a heterodimer with HIF-1𝛽 leading to the binding to 
hypoxia response elements (HREs). This binding increases activation of transcription and 
expression of several target genes, such as the glycolytic enzymes, vascular endothelial growth 
factor (VEGF) that leads to angiogenesis, as well as proapoptotic genes (Vangeison et al, 2008; 
Yokogami et al, 2013).  
 
Mu-Opioid Receptor Regulation 
 
 Many compounds have been identified to create the hypoxic mimic condition; these 
hypoxic mimicking compounds include cobalt chloride (CoCl2) (Wang and Semenza, 1993), 
nickel chloride (NiCl2), and desferoxamine (DFO) (Wang and Semenza, 1993). DFO acts as a 
ferrous iron chelator and inhibits the prolyl hydroxylases that are essential for the proteaosomal 
degradation of HIF-1𝛼 (Harris, 2002).  Increased DFO concentration has been shown to reduce 
neuronal NMB cell viability and increase cellular glutathione levels in the surviving cells (Figure 
1A; Cook et al, 2010). The neurons that survived the DFO insult also do not exhibit any significant 
morphological changes in comparison to the non-treated neuronal cells. (Figure 1B; Cook et al, 
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2010). The surviving cells, however, did present with increased endogenous HIF-1 mRNA levels 
over extended exposure to DFO (Figure 1C; Cook et al, 2010).  Another important feature was the 
decrease in mu-opioid receptor (MOR) mRNA levels within DFO treated cells. Opioid receptors 
are known to mediate pain sensation and they may also play a role in the survival. However, there 
are controversial results in MORs role in neuroprotection (Feng et al, 2012).  
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Figure 1: (A) Human NMB cells were treated with varying concentrations of DFO for 24 hours. 
Viability was measured (open circles) as the percentage of total cell number divided by the control 
(100%). Glutathione levels were measured similarly. Cell viability and glutathione levels were 
also measured in cells treated with 200 𝜇M DFO for 2, 4, and 24 hours. (B) Effect of DFO exposure 
on cellular morphology of NMB cells. Cells surviving, control (no treatment), DFO, and hydrogen 
peroxide (positive control) exposure were stained using annexin-V-FLUOS (green color) and PI 
(red color). Images were obtained using confocal microscopy. (C) DFO treatment increases the 
expression of HIF-1 mRNA levels. Cells were treated with DFO for 2, 4, 8, 12, and 24 hours. RNA 
was extracted from cells without (control) and with DFO treatment. RT-PCR was performed using 
specific primers for HIF-1 and beta-actin (internal standard). (D) Effect of DFO on MOR mRNA 
levels. Cells were treated with DFO for 2, 4, 8, 12, and 24 hours. RNA was extracted from cells 
without (control) and with DFO treatment. RT-PCR was performed using specific primers for 
MOR and beta-actin (internal standard). (A-C) Adapted from Cook et al, 2010. 
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MOR expression and activation has been significantly studied, due to morphine’s high 
affinity for the receptor, for inducing analgesia and tolerance (Le Merrer et al, 2009). These 
characteristics have made MOR the focus of pain management and addiction; and have led to the 
discovery of a reduction in functional MORs upon chronic opioid treatment (Christie et al, 1987). 
However, the exact mechanisms for the regulation of functional MORs under various conditions 
have yet to be completely uncovered (Le Merrer et al, 2009). One of the transcriptional regulators 
for the regulation of MOR gene expression was identified as poly C binding protein 1 (PCBP1), 
in both mouse (Ko and Loh, 2005) and human species (Cook et al, 2010; Nahar-Gohad et al, 2013). 
PCBP1 has been shown to participate in multiple levels of gene expression, from stimulating 
transcription, regulating RNA splicing and acting as a translational repressor (Choi et al, 2009). 
Recently, a new role for PCBP1 was discovered (Nahar-Gohad et al, 2013). It has been shown to 
directly interact with RACK-1, receptor activated C-kinase (Figure 2; Nahar-Gohad et al, 2013), 
and using human neuronal NMB cells RACK-1’s interaction with PCBP-1 causes a decrease in 
the available PCBP-1, not allowing translocation of the transcriptional regulator into the nucleus 
to initiate transcription (Nahar-Gohad et al, 2013). Therefore, this study determined whether such 
a regulatory mechanism occurs under the hypoxia condition.   
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Figure 2: (A) Co-immunoprecipitation of PCBP1-RACK1. Using Western Blot analysis, whole 
NMB cell lysates were incubated with anti-PCBP1 or a non-specific IgG antibody (control). The 
same lysates were then probed with anti-RACK1 antibody. (B) Determination of RACK1-PCBP1 
interaction domain using deletional analysis. Illustrates full length RACK1 and truncated RACK1 
fragments. Each was cloned into pTRG vectors and each construct was co-transformed with 
full length PCBP1 using the two-hybrid system. Interaction between RACK1 and PCBP1 was 
determined by growth ability. Illustrates full-length RACK1 and individual domain 
constructs used to determine the interaction capability between RACK1 and PCBP1 using the 
two-hybrid system. Also present is the amino acid comparison of all RACK1 WD domains, 
with conserved amino acids highlighted. (A-B) Adapted from Nahar-Gohad et al, 2013.  
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JAK/STAT Activation and Suppression  
 
Several signal transduction pathways are known to be involved in cell survival. Previous 
experimentation has shown the activation of the JAK/STAT pathway under DFO induced hypoxia 
(Rasmussen, 2012). The activation of the JAK/STAT pathway leads to many processes that 
stimulate cell proliferation, differentiation, migration, and apoptosis, all of which are required to 
support homeostasis (Rawlings et al, 2004).  
Signaling through the JAK/STAT pathway can be initiated by a variety of ligands and their 
receptors. Ligands, such as cytokines (examples: interleukin (IL)-6, IL-11, and interferon (IFN)-
alpha) bind to their receptors inducing dimerization of JAKs, which associate with the cytoplasmic 
domains of the receptor (Inagaki-Ohara et al, 2013; Yu et al, 2007). Dimerization leads to 
autophosphorylation of the JAK units at specific tyrosine residues, these residues further act as 
docking sites for transcription factors. Signal transduction and activation of transcription (STATs) 
factors are one of the main groups of transcription factors that interact with the activated JAK and 
become phosphorylated (p-STAT) at tyrosine residues. The p-STAT dimerizes for translocation 
into the nucleus where it will influence the initiation and transcription of multiple target genes. For 
example, STAT3, the protein of interest within these experiments, targets anti-apoptotic genes, 
pro-proliferation genes, and angiogenesis (Yu et al, 2009; Ogura et al, 2008; Yokogami et al, 
2013). Regulation of the JAK/STAT pathway is mediated through a series of proteins known as 
suppressors of cytokine signaling (SOCS). These proteins produce a negative feedback loop to 
prevent excess activation of the JAK/STAT pathway (Qin et al, 2012).  
               This study therefore, examined the inhibition of pathways under the hypoxic response. 
The balance between the activation and the suppression of the JAK/STAT pathway is delicate and 
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important for normal homeostatic function (Rawlings et al, 2004). There are eight members of the 
SOCS family (SOCS1-7 and CIS), all of which are characterized by a homologous SH2 domain 
that allows their binding to tyrosine phosphorylated molecules and a C-terminal SOCS box that is 
essential for ubiquitination (Boyle et al, 2009; Babon et al, 2012). Two of the eight inhibitory 
proteins are considered potent suppressors, SOCS1 and SOCS3, which have an additional kinase 
inhibitory region (KIR) located near the N-terminal (Boyle et al, 2009).  The KIR region allows 
for direct inhibition of JAK activity (Babon et al, 2012). It has been suggested that SOCS3 binds 
to both the JAKs and the receptor simultaneously, which leads to inhibition of specific cytokine 
produced signals (Babon et al, 2012). SOCS3 has been shown to be a non-competitive inhibitor of 
JAK, specifically inhibiting the ability to transfer a phosphate to the specific tyrosine of the 
adapting molecule (Inagaki-Ohara et al, 2013).  
Irregularities in the activation of STAT3, such as overexpression or activation, can lead to 
increased expression of genes required for proliferation, survival, angiogenesis, and inflammation 
(Yu et al, 2009). The overexpression of these genes leads to tumorigenesis due to reduced 
expression of SOCS3, which is the main regulator of STAT3. For example, due to STAT3 
activation and translocation, an increase in the growth factor VEGF can be seen (Yokogami et al, 
2013). The increase is VEGF further activates the JAK/STAT3 pathway to create a mechanism 
that continuously ensures the presence of STAT3 in tumor cells (Yu et al, 2007). It has been shown 
that SOCS3 is essential for the regulation of cancer progression. In the pancreas, through the 
deletion of SOCS3, aberrant expression of STAT3 escalates the progression of pancreatic 
intraepithelial neoplasias and pancreatic ductal adenocarcinoma through the IL-6 activated 
STAT3/SOCS3 pathway (Lesina et al, 2011). SOCS3 has been suggested to function as a tumor 
suppressor that undergoes down regulation through hypermethylation of the SOCS3 promoter in 
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a variety of cancers (Inagaki-Ohara et al, 2013). However, SOCS3 is continuously expressed in 
melanoma cells, which may suggest a protective function (Fojtova et al, 2007). Previously, an 
increase in p-STAT3 has been seen within neuronal cells treated for extended periods of time with 
DFO (Figure 3; Rasmussen, 2012; unpublished data), which would lead to the assumption that 
SOCS3 levels would be low. Due to the inconsistency in the expression of SOCS3 between 
cancers, it is necessary to further understand the relationship between SOCS3 and other 
microenvironment conditions, such as hypoxia in this study.  
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Figure 3: Phosphorylated STAT3 expression under extended exposure to DFO. NMB cells were 
exposed to DFO for 4, 6, 8, 12, and 24 hours. Western blot analysis revealed p-STAT3 levels. 
Quantification of p-STAT3 was done by normalization with beta-tubulin. Values are shown +/-
SE. “**” Indicating a p value less than 0.005. (Rasmussen, 2012, unpublished data). 
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Materials and Methods 
 
 
Cell Culture: 
 
Human Neuroblastoma cells (NMB) were maintained in Roswell Park Memorial Institute 
Media (RPMI) (Invitrogen, CA) with 10% Fetal Bovine Serum infused with antibiotics, 
streptomycin and penicillin, in a 37 degrees Celsius and 5% CO2  incubator. Cells were treated with 
single doses of 0.1 mM of desferoxamine (DFO) and incubated for varying exposure times. The 
DFO used is a product of Sigma-Aldrich (St. Louis, MO).  
 
RNA Isolation: 
Total RNA was extracted using Tri-reagent (Invitrogen, CA) and chloroform. The mixture 
was then centrifuged at 12000 RPM for 5 minutes at 4 degrees Celsius. The top phase, of the three 
phase separation, was removed as it contained the RNA, which was precipitated using isopropanol 
(molecular grade, Sigma-Aldrich). The mixture then underwent centrifugation for 5 minutes at 
12000 RPM and 4 degrees Celsius. The RNA pellet was washed with 70% ethanol and allowed to 
dry. The pellet was resuspended in diethyl pyrocarbonate (DEPC) treated water. Concentration of 
the RNA was determined through spectrophotometry and calculated using absorbance at 260 nm.  
 
RT-PCR: 
Reverse transcription was performed using RNA for the synthesis of first strand cDNA and 
random hexamer primer (Qiagen, CA). The cDNA was synthesized for 50 minutes at 37 degrees 
Celsius and 15 minutes at 70 degrees Celsius. PCR amplification was performed under the settings 
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of 95 degrees Celsius for 1 minute, 68 degrees Celsius for 30 seconds annealing, and 72 degrees 
Celsius for 30 seconds for 32 cycles of the MOR gene. RACK1 gene amplification was performed 
under the settings of 95 degrees Celsius for 1 minute, 67 degrees Celsius for 30 seconds, and 72 
degrees Celsius for 30 seconds over 21 cycles.  
 
Agarose Gel Electrophoresis: 
The products of PCR amplification were run on 2% aragose gels which contained ethidium 
bromide. Samples were allowed to separate for 30 minutes at 120 volts. Images of the gel and 
products were taken utilizing Alpha Imager with UV illumination. All products underwent 
quantification using Image Quant version 5.2.  
 
Statistical Analysis 
 All acquired data was normalized and presented as +/- SEM. Statistical comparison 
between the groups, control and treatments, were preformed by use of the Student T-Test. All 
analysis was completed by use of InStat with statistical significance defined as P<0.05.  
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Results 
 
Determination of MOR mRNA levels under hypoxia 
 
The prevalence of hypoxia in many diseases as well as in operative and post-operative 
scenarios makes the mechanism by which MOR is regulated an important research objective. In 
addition, MOR is involved in the management of pain; therefore, the expression of MOR was 
investigated under the influence of DFO induced hypoxia in this study. Previous results have 
shown a decrease in MOR mRNA levels during various exposure periods of DFO treatment 
(Figure 1D). To determine if the decrease of MOR expression was maintained during a longer 
DFO exposure (48 hours), the level of MOR mRNA was examined. RNAs were extracted from 
NMB neuronal cells treated with DFO for 2, 4, 8, 12, 24, and 48 hours or with no treatment 
(control). RT-PCR was performed with specific MOR primers as well as beta-actin primers and 
PCR products were analyzed. Beta-actin was used as an internal standard for normalization. Figure 
4 shows the gradual decrease in the mRNA levels of MOR over the time course.  These results 
show that the mRNA levels of MOR gradually decreased significantly from 12 hours (p<0.001), 
24 hours (p<0.001), and 48 hours (p<0.001) upon exposure to DFO.   
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Figure 4: Expression of MOR mRNA in NMB cells under DFO exposure 
(A) Results from RT-PCR analysis showing MOR gene expression in NMB cells treated with DFO 
with beta-actin as an internal control for normalization. Image shows the expression of MOR in 
treated and nontreated (control) samples of NMB cells plated (1 x 10^6), treated with 300 𝜇M of 
DFO at 2, 4, 8, 12, 24, and 48 hours, and analyzed on a 2% agarose gel. (B) Normalized mRNA 
levels from control were defined as 100%. Quantitative analyses from five different experiments 
are presented as mean±SE, “***” indicating P<0.001.   
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Determination of RACK1 mRNA levels under hypoxia 
 
 Recently, our laboratory has demonstrated that RACK1 can negatively regulate MOR 
expression (Figure 2; Nahar-Gohad et al, 2013). RACK1 acts as a scaffolding protein and directly 
interacts with PCBP1, the MOR transcriptional regulator (Nahar-Gohad et al, 2013). Therefore, to 
examine if the RACK1 message was increased under DFO treatment, the expression of RACK1 
under DFO-induced hypoxia was examined. RNAs were extracted from neuronal NMB cells 
treated without or with DFO for 2, 4, 8, 12, 24, and 48 hours. RT-PCR was performed with specific 
RACK1 primers as well as with beta-actin primers and the PCR products were analyzed. Beta-
actin was used as an internal standard for normalization. Figure 5 shows the gradual increase in 
the mRNA levels of RACK1 overtime. The results show that the mRNA levels of RACK1 
gradually increase significantly from 24 hours (P<0.01) to 48 hours (P<0.001) upon exposure to 
DFO. Taken together, Figure 4 and Figure 5 show an inversely proportional relationship between 
the mRNA expression of MOR and the mRNA expression of RACK1.   
 22 
 
Figure 5: Expression of RACK1 mRNA in NMB under DFO exposure 
(A) Results from RT-PCR analysis showing RACK1` gene expression in NMB cells treated with 
DFO with beta-actin as an internal control for normalization. Image shows the expression of 
RACK1 in treated and nontreated (control) samples of NMB cells plated (1 x 10^6), treated with 
300 𝜇M of DFO at 2, 4, 8, 12, 24, and 48 hours, and analyzed on a 2% agarose gel. (B) Normalized 
mRNA levels from control were defined as 100%. Quantitative analyses from nine different 
experiments are presented as mean±SE, “**” indicating P<0.01 and “***” indicating a P<0.001.  
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JAK/STAT Activation and Suppression  
 
Determination of SOCS3 mRNA levels under hypoxia 
 
 Activation of the JAK/STAT pathway is crucial in the maintenance of homeostasis, and it 
can affect both proliferation and apoptosis by phosphorylation of STAT3; conditional on the 
initiation of specific target genes (Inagaki-Ohara et al, 2013). Formerly, Western Blot analyses 
showed that the level of p-STAT3 was activated within neuronal cells under DFO-induced hypoxia 
over a time course (Figure 3; Rasmussen, 2012; unpublished data). Results of these analyses show 
a significant increase in p-STAT3 levels at 12 and 24 hours (p<0.005).   
The delicate balance between activation and suppression is key for normal homeostatic 
function. Therefore, the presence of an inhibitory mechanism to prevent excess JAK/STAT 
activation, such as the increase of SOCS3 levels, is essential. The levels of SOCS3 mRNA were 
then investigated. RNAs were extracted from neuronal NMB cells treated without or with DFO 
for 2, 4, 8, 12, 24, and 48 hours. RT-PCR was performed with specific primers for SOCS3 as well 
as with primers for beta-actin. PCR products were analyzed via gel electrophoresis. Beta-actin was 
used as the internal standard for normalization. Figure 6 showed the gradual increase in the mRNA 
levels of SOCS3 overtime. In summary, these results demonstrated that the mRNA levels of 
SOCS3 gradually increase with a significant increase seen at 24 hours (P<0.05) and48 hours 
(P<0.005) upon the exposure to DFO.  
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Figure 6: Expression of SOCS3 mRNA in NMB under DFO exposure 
(A) Results from RT-PCR analysis showing SOCS3 gene expression in NMB cells treated with 
DFO with beta-actin as an internal control for normalization. Image shows the expression of 
SOCS3 in treated and nontreated (control) samples of NMB cells plated (1 x 10^6), treated with 
300 𝜇M of DFO at 2, 4, 8, 12, 24, and 48 hours, and analyzed on a 2% agarose gel. (B) Normalized 
mRNA levels from control were defined as 100%. Quantitative analyses from nine different 
experiments are presented as mean±SE, “*” indicating P<0.05 and “**” indicating P<0.005.  
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Discussion 
 
 Cancer, disease, surgery, or traumatic injury can elicit the hypoxic condition and can 
further instigate pain sensation mediated through MORs. Therefore, it was important to investigate 
the mechanism of MOR expression under DFO induced hypoxia. In this study, we report that the 
data gathered under DFO induced hypoxia follows the theory that MOR mRNA expression 
reduction is a direct affect of the interaction between PCBP1, the MOR transcriptional regulator, 
and RACK1.  
Under DFO induced hypoxia, NMB neuronal cells have shown a decrease in MOR mRNA 
levels over increased exposure times (Cook et al, 2010).  In this study, the decrease is MOR mRNA 
levels under DFO induced hypoxia was verified and shows consistency with previous studies 
performed. In addition, MOR mRNA levels remained low under longer exposure to DFO (Figure 
4). MOR expression has been shown to be regulated by PCBP1 at the level of transcription (Ko 
and Loh, 2005; Malik et al, 2006; Rivera-Gines et al, 2006; Cook et al, 2010) and has since been 
shown, though two-hybrid screening and co-immunoprecipitation, that there is a direct interaction 
between PCBP1 and RACK1 (Nahar-Gohad et al, 2013). Here, through mRNA analysis, MOR 
mRNA levels decreased over increased exposure times to DFO (Figure 4) while RACK1 mRNA 
levels increased over the same exposure times (Figure 5). These results agreed that DFO induced 
hypoxia influences a reduction in MOR expression via the same PCBP1-RACK1 interaction as 
shown in our lab’s recent publication (Figure 7; Nahar-Gohad et al, 2013).  
There is a long history of the use of opioid receptors as pain modulators. MOR has been 
extensively studied due to its actions in the mediation of morphine (Al-Hasani and Bruchas, 2011; 
Feng et al, 2012), which has lead to the inquiry of MORs potential affect on pain sensation due to 
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hypoxia. Under hypoxia, sensitization of high-threshold receptors allows an increase in pain with 
disease progression (Regan and Peng, 2000). A decrease in MOR mRNA expression has also been 
seen in the studies of many diseases such as fibromyalgia (Harris et al, 2007) and opiate addiction 
(Feng et al, 2012), as well as in studies of inflammatory pain (Aoki et al, 2014). The decrease in 
the availability of functional MORs lead to an increase in pain, as well as a decrease in the ability 
to treat pain with opiates (Harris et al, 2007; Aoki et al, 2014). With RACK1 playing a negative 
regulatory role in the regulation of MOR gene expression (Nahar-Gohad et al, 2013), this raises 
the question of what elevates RACK1 expression. This study, therefore, implicated that the change 
of RACK1 expression can be pathologically mediated; down-regulation or up-regulation of 
RACK1 seems to depend on the pathological location.  
Alterations in RACK1 expression are associated with a variety of disorders; including brain 
development disorders, heart failure, renal failure, cancer, and others (Adams et al, 2011).  
Elevation in the expression of RACK-1 has been proposed to be a marker of prognosis in breast 
cancer (Cao et al, 2010) and elevation in expression has also been seen in various other cancers 
such as heptacellular carcinoma (Ruan et al, 2012), and melanoma (Lopez-Bergami et al, 2007). 
This data suggests that the increase in RACK1 expression reduces the ability to manage pain by 
decreasing the amount of MOR receptors available on the cells surface, which supports the notion 
that hypoxia can augment pain sensation due to the decrease in MOR expression (Regan and Peng, 
2000). However, where the exact mechanism initiates MOR down-regulation and/or up-regulation 
of RACK1 will requires more comprehensive studies.  
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Figure 7: Simplified diagram showing the modularity of PCBP1 in MOR expression. PCBP1 
(black) can be free to translocate into the nucleus to bind to DNA and initiate the transcription of 
the MOR mRNA that will then be translated into a functional receptor. When RACK1 (White) is 
available, PCBP1 (Black) with bind to RACK1, which will keep the transcriptional regulator from 
translocating into the nucleus to initiate transcription and leads to a decrease in the expression of 
MOR mRNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Nahar-Gohad et al, 2013. 
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JAK/STAT Activation and Suppression  
 
The balance between activation and inhibition of pathways is important to maintain 
homeostasis and adaptation for cell survival. Neuronal cells that survived the influence of DFO 
have shown evidence of JAK/STAT pathway activation by the presence of p-STAT3 observed by 
Western blot analysis. The detected signal for p-STAT3 was also observed to increase over 
exposure to DFO (Figure 3; Rasmussen, 2012; unpublished data). Together, these results lead to 
the investigation of the pathways main inhibitor, SOCS3, which is essential to maintain the balance 
between phosphorylated STAT3 and further activation of the pathway (Rawlings et al, 2004).  
 In this study, RT-PCR has shown an increase in mRNA levels of SOCS3 under increased 
exposure times to DFO (Figure 6), while the p-STAT3 signal also increased (Figure 3; Rasmussen, 
2012; unpublished data). Together, these results indicated that the balance between the JAK/STAT 
pathway and SOCS3 may be important for neuroprotection under DFO-induced hypoxia 
challenge. Certainly, more studies will be required to determine the function and the related 
mechanisms.  
SOCS3 inhibits through direct interaction with the JAK subunits and the related receptors 
simultaneously, blocking the phosphorylation sites that are required for further phosphorylation of 
the STAT3 factors and preventing advancement of signal (Babon et al, 2012; Kershaw et al, 2013). 
Over expression of SOCS3 has been seen in human neuroblastoma and is suggested to decrease 
the protective effect of STAT3 mediated insulin-like growth factor against TNF-α induced cell 
death (Baker et al, 2009).  However, the increased presence of SOCS3 has been suggested to be 
correlated to the severity of inflammation. Inflammatory studies performed on a murine model of 
periodontal disease has shown a parallel increase is SOCS3 and p-STAT3 over the duration of 
inflammation and has led to the suggestion that the negative regulation that SOCS3 provides is 
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important for the regulation of expression of genes that are responsible for connective tissue 
degradation (Chaves de Souza et al, 2013).   A similar elevation pattern in the expression of both 
STAT3 and SOCS3 has also been seen in glioblastoma and is suggested to contribute to its anti-
apoptotic phenotype and malignancy (Baker et al, 2009). Together, these results reveal the 
controversy that plaques SOCS3’s function and mechanism, as well as provides the reasoning for 
further exploration of its role in inflammation and neuroprotection.  
 Previously, Cook et al reported the increase in HIF-1 in neuronal NMB cells under DFO 
induced hypoxia at increasing exposure times, while the experiments presented here show an 
increase in SOCS3 under the same conditions (Figure 6). Interestingly, this parallel increase is 
similar to what has been seen in adipocytes under CoCl2 induced hypoxia. Through ChIP assays, 
the SOCS3 gene was determined to possess two potential HREs and shown to be a direct target of 
HIF-1 (Jiang et al, 2013).  These reported results suggest a more complex mechanism behind 
SOCS3 expression that goes beyond the concentration of p-STAT3 present within the activated 
pathway. More experimental analysis could lead to more mechanical similarities between the 
studies and may lead to a further understanding of the role SOCS3 plays in neuroprotection under 
DFO induced hypoxia.  
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